Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $0.79 Analyst target: $9.11 Upside: 1049.09%
Tvardi Therapeutics, Inc. is an innovative clinical-stage biopharmaceutical company focused on developing novel oncology therapies to meet critical unmet medical needs. Leveraging its proprietary drug discovery platform, Tvardi specializes in small molecule therapies designed to target protein degradation pathways, enhancing the effectiveness of cancer treatments. Its lead candidate, TVB-2640, is engineered to disrupt cancer cell survival mechanisms, reflecting the company's commitment to offering transformative therapeutic options. With a robust pipeline and a strong emphasis on scientific excellence, Tvardi is well-positioned to significantly influence the future of cancer treatment.
See the full interactive analysis & chart →Informational only — not investment advice.